Use of a supplement called Memovigor-2 in tinnitus (a condition where a person hears a ringing or buzzing sound in their ears)

Memovigor-2 improves tinnitus in patients with recent onset disease: A randomized placebo-controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16025480

Enrollment

160

Registered

2023-04-05

Start date

2019-12-09

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus Ear, Nose and Throat

Interventions

Patients participating in the research group (50%) are given 1 tablet 900 mg of Memovigor 2 (Bionat, Athens, Greece) daily for 3 months. Similar use of placebo is used in the remaining 50%, the contro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18 - 70 years 2. Suffering from tinnitus 3. Recent onset disease =12 months

Exclusion criteria

Exclusion criteria: 1. Patients with otosclerosis 2. Chronic otitis media 3. Hypo- or hyperthyroidism 4. Diabetes mellitus 5. Uncontrolled hypertension 6. Hypercholesterolemia 7. Coagulation disorders 8. Use of anticoagulants

Design outcomes

Primary

Measure	Time frame
Tinnitus change is measured using Tinnitus Handicap Inventory questionnaire (THI) at baseline and 3 months	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 04/07/2023: 1. Tinnitus severity is measured using Mini Tinnitus Questionnaire at baseline and 3 months 2. Evaluation of perceptional quality of tinnitus using specific measures of tinnitus perception (tinnitus loudness matching, tinnitus pitch matching, tinnitus minimum masking level, residual inhibition of tinnitus) at baseline and 3 months 3. Evaluation of hearing is measured using audiometry at baseline and 3 months 4. Perception of tinnitus change due to intervention measured using the Patient's Global Impression of Change (PGIC) at baseline and 3 months Previous secondary outcome measures: 1. Tinnitus severity is measured using Mini Tinnitus Questionnaire at baseline and 3 months 2. Objective tinnitus evaluation is measured using objective tinnitus measurement tests (tinnitus loudness matching, tinnitus pitch matching, tinnitus minimum masking level, residual inhibition of tinnitus) at baseline and 3 months 3. Evaluation of hearing is measured using audiometry at baseline and 3 months.	—

Measure

Time frame

Current secondary outcome measures as of 04/07/2023: 1. Tinnitus severity is measured using Mini Tinnitus Questionnaire at baseline and 3 months 2. Evaluation of perceptional quality of tinnitus using specific measures of tinnitus perception (tinnitus loudness matching, tinnitus pitch matching, tinnitus minimum masking level, residual inhibition of tinnitus) at baseline and 3 months 3. Evaluation of hearing is measured using audiometry at baseline and 3 months 4. Perception of tinnitus change due to intervention measured using the Patient's Global Impression of Change (PGIC) at baseline and 3 months Previous secondary outcome measures: 1. Tinnitus severity is measured using Mini Tinnitus Questionnaire at baseline and 3 months 2. Objective tinnitus evaluation is measured using objective tinnitus measurement tests (tinnitus loudness matching, tinnitus pitch matching, tinnitus minimum masking level, residual inhibition of tinnitus) at baseline and 3 months 3. Evaluation of hearing is measured using audiometry at baseline and 3 months.

—

Countries

Greece

Contacts

Public ContactDimitrios Balatsouras

hospital@tzaneio.gr+30 2104592644

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026